Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 3
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 y…
Epidermolysis Bullosa (EB)
Estimated
~$10 – $8,750
Paradigm TherapeuticsNCT07482787
Phase 2
A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa
This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel i…
Epidermolysis Bullosa (EB)Dystrophic Epidermolysis BullosaJunctional Epidermolysis Bullosa
Estimated
~$10 – $7,500
Xinnate ABNCT06594393
Phase 1
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Ep…
Epidermolysis Bullosa (EB)Epidermolysis Bullosa AcquisitaRecessive Dystrophic Epidermolysis Bullosa+1 more
Estimated
~$10 – $7,500
M. Peter MarinkovichNCT07011589